# Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

> **NCT03299946** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 15 (actual)

## Conditions studied

- Locally Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03299946
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-14
- **Primary completion:** 2019-12-09
- **Final completion:** 2021-10-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299946, "Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03299946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*